Sanofi SA Nirsevimab R&D Investor Event Transcript
Good afternoon, and good evening to Asia. I'm Eva Schaefer-Jansen of Sanofi Investor Relations. Welcome to this event. This is the fifth in a series of 5 R&D events, highlighting the accelerating pipeline momentum building within Sanofi R&D.
Today, we will focus on the Phase IIb results of nirsevimab just published in the New England Journal of Medicine. As usual, you can find the slides to this call on the Investors page of our website at sanofi.com. Next slide, please.
So I would like to remind you that information presented during this event contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document dâEnregistrement Universel for a description of these factors. Next slide, please.
So I would like to introduce you to our speakers today. We have here Thomas Triomphe, Global Head of Sanofi Pasteur; we have Su-Peing Ng, Global Head of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
